Univariate analysis for overall survival, disease-free survival, and transplantation-related mortality
| Variable . | OS at 1 y . | P . | DFS at 1 y . | P . | NRM at d 100 . | P . |
|---|---|---|---|---|---|---|
| Age < 52 (43) | 35.8 | 31.7 | 44.3 | |||
| Age > 52 (43) | 33.5 | NS | 25.4 | NS | 39.8 | NS |
| Male (52) | 33.3 | 29.6 | 39.0 | |||
| Female (34) | 34.8 | NS | 25.9 | NS | 47.1 | NS |
| AML (43) | 39.1 | 34.7 | 39.8 | |||
| CML (27) | 31.7 | 34.0 | 40.7 | |||
| Other (16) | 25.0 | NS | 6.25 | NS | 50.0 | NS |
| < 18 m to SCT (42) | 39.2 | 28.3 | 33.3 | |||
| > 18 m to SCT (44) | 29.9 | NS | 28.0 | NS | 50.1 | NS |
| Good risk (7) | 57.1 | 57.1 | 42.9 | |||
| Intermediate (16) | 56.2 | 50.0 | 37.5 | |||
| Bad risk (63) | 25.4 | NS | 19.0 | .04 | 32.2 | NS |
| Prior SCT | ||||||
| No (62) | 38.7 | 30.2 | 38.8 | |||
| Yes (24) | 23.4 | NS | 23.8 | NS | 40.6 | NS |
| Prior Rx | ||||||
| < 3 (43) | 53.0 | 45.2 | 32.6 | |||
| ≥ 3 (43) | 16.5 | .002 | 11.9 | .001 | 51.8 | .03 |
| PS < 2 (72) | 40.9 | 33.8 | 33.9 | |||
| PS ≥ 2 (14) | 0.0 | < .0001 | 0.0 | < .0001 | 81.0 | < .0001 |
| FM180/140 (78) | 36.4 | 29.8 | 37.4 | |||
| 2CDA/M (8) | 12.5 | .005 | 12.5 | .006 | 87.5 | .0001 |
| BM (52) | 26.0 | 22.3 | 46.4 | |||
| PB (34) | 50.0 | NS | 38.6 | NS | 35.3 | NS |
| Related (46) | 36.7 | 27.6 | 32.6 | |||
| Unrelated (40) | 31.8 | NS | 29.1 | NS | 53.0 | .05 |
| Male donor (44) | 49.5 | 42.0 | 36.4 | |||
| Female donor (42) | 14.4 | .006 | 11.4 | .003 | 48.1 | .06 |
| Variable . | OS at 1 y . | P . | DFS at 1 y . | P . | NRM at d 100 . | P . |
|---|---|---|---|---|---|---|
| Age < 52 (43) | 35.8 | 31.7 | 44.3 | |||
| Age > 52 (43) | 33.5 | NS | 25.4 | NS | 39.8 | NS |
| Male (52) | 33.3 | 29.6 | 39.0 | |||
| Female (34) | 34.8 | NS | 25.9 | NS | 47.1 | NS |
| AML (43) | 39.1 | 34.7 | 39.8 | |||
| CML (27) | 31.7 | 34.0 | 40.7 | |||
| Other (16) | 25.0 | NS | 6.25 | NS | 50.0 | NS |
| < 18 m to SCT (42) | 39.2 | 28.3 | 33.3 | |||
| > 18 m to SCT (44) | 29.9 | NS | 28.0 | NS | 50.1 | NS |
| Good risk (7) | 57.1 | 57.1 | 42.9 | |||
| Intermediate (16) | 56.2 | 50.0 | 37.5 | |||
| Bad risk (63) | 25.4 | NS | 19.0 | .04 | 32.2 | NS |
| Prior SCT | ||||||
| No (62) | 38.7 | 30.2 | 38.8 | |||
| Yes (24) | 23.4 | NS | 23.8 | NS | 40.6 | NS |
| Prior Rx | ||||||
| < 3 (43) | 53.0 | 45.2 | 32.6 | |||
| ≥ 3 (43) | 16.5 | .002 | 11.9 | .001 | 51.8 | .03 |
| PS < 2 (72) | 40.9 | 33.8 | 33.9 | |||
| PS ≥ 2 (14) | 0.0 | < .0001 | 0.0 | < .0001 | 81.0 | < .0001 |
| FM180/140 (78) | 36.4 | 29.8 | 37.4 | |||
| 2CDA/M (8) | 12.5 | .005 | 12.5 | .006 | 87.5 | .0001 |
| BM (52) | 26.0 | 22.3 | 46.4 | |||
| PB (34) | 50.0 | NS | 38.6 | NS | 35.3 | NS |
| Related (46) | 36.7 | 27.6 | 32.6 | |||
| Unrelated (40) | 31.8 | NS | 29.1 | NS | 53.0 | .05 |
| Male donor (44) | 49.5 | 42.0 | 36.4 | |||
| Female donor (42) | 14.4 | .006 | 11.4 | .003 | 48.1 | .06 |
OS indicates overall survival; DFS, disease-free survival; NS, not significant; SCT, stem cell transplantation; Rx, therapy; BM, bone marrow; PB, peripheral blood; for other abbreviations see Tables 1-4.